Capabilities by Region

Greenhill is active in all major markets with meaningful corporate advisory activity, including in North America, Europe,  Asia, and Australia.

Recent Transactions

01-Jun-16
$221 million
Australia flag
Target: 

Patties Foods Ltd

Australia flag
Acquiror: 
Pacific Equity Partners

Advised Patties Foods Ltd (ASX:PFL), the leading Australian branded frozen food Company, with market leadership in the frozen savoury and frozen dessert segments, on its proposed sale to Pacific Equity Partners via Scheme of Arrangement

26-May-16
$500 million
Egypt, U.S. flags
Target: 

Apex International Energy Management LLC

flag not available

Advised Apex International Energy Management, a newly formed oil and gas venture focused on the Middle East and North Africa regions, in the private equity fund-raising process with multiple energy-focused financial sponsors, ultimately resulting in an initial $500 million capital commitment from Warburg Pincus.

16-May-16
$874 million
U.K., Netherlands, Germany flags
Target: 

Equinix Data Center Assets

United States flag
Acquiror: 
Digital Realty Trust

Advised Digital Realty Trust, the world's largest wholesale colocation services and data center solutions provider, on its acquisition of a portfolio of eight carrier-neutral European data centers from Equinix

10-May-16
$NA
Brazil flag
Target: 

Brasil/CT

Brazil flag
Acquiror: 
Invest Tech

Advised Brasil/CT on a capital injection made by Invest Tech in the Company.  Brasil/CT specializes in the e-commerce market and is a leader in B2C and B2B full-commerce and loyalty operations in Brazil.  Invest Tech is an investment manager focused on venture capital and private equity in the technology and telecom sectors

04-May-16
$NA
United States flag
Target: 

Portfolio of synthetic royalty and milestone rights on multiple cardiovascular programs

United States flag
Acquiror: 
Ligand Pharmaceuticals

Advised CorMatrix Cardiovascular, a leading medical device company with a differentiated extracellular matrix technology, on the sale of a portfolio of synthetic royalty and milestone rights on multiple cardiovascular programs

Pages

show all